Heart failure is a condition where the heart can’t pump well enough to deliver oxygen to the organs effectively. Ejection fraction is a term used to describe the amount of blood pumped out compared with the total blood the heart can hold. In a healthy heart, 50-70% of blood is ejected with each heartbeat.

We are conducting a clinical research study for people who have heart failure with a reduced ejection fraction (<50%). This study will evaluate the safety and tolerability of a new investigational drug.

You may be eligible if you:

• Are between 18 and 80 years old
• Have heart failure
• Have a left ventricular ejection fraction (LVEF) of <50%
• Have been taking a stable dose of sacubitril/valsartan (Entresto) for at least 4 weeks.
• Have been taking a stable dose of a beta blocker for at least 4 weeks.
  • Examples of beta blockers:
    • Acebutolol
    • Atenolol (Tenormin)
    • Bisoprolol (Zebeta)
    • Metoprolol (Lopressor, Toprol XL)
    • Nadolol (Corgard)
    • Nebivolol (Bystolic)
    • Propranolol (Inderal, InnoPran XL)

Volunteers must be able to complete multiple overnight stays at our phase 1 clinic for this study. There are additional criteria to meet to qualify for this study. Volunteers who qualify for our study will receive study-related medication and study-related medical exams at no cost, along with a stipend for time and travel. No health insurance is required to participate.

For more information call:
(904) 730-0166 (Jacksonville)
(352) 341-2100 (Inverness)

Or sign up below!

Read the latest posts by our expert clinical staff!